Investment Thesis
Neurocrine demonstrates exceptional fundamental strength with revenue growth of 21.4% YoY coupled with outstanding net income growth of 40.2% YoY, indicating significant operating leverage and margin expansion. The company maintains a fortress-like balance sheet with zero meaningful debt, strong liquidity (2.93x current ratio), and robust free cash flow generation of $136.7M, providing financial flexibility and downside protection.
Strengths
- Outstanding growth profile with 21.4% revenue growth and 40.2% net income growth demonstrating strong operating leverage and margin expansion
- Fortress balance sheet with zero debt (0.00x debt/equity), exceptional liquidity (2.93x current ratio), and robust free cash flow of $136.7M
- Exceptional profitability with 24.3% net margin and 23.7% operating margin, well above industry average for biotech
Risks
- Biotech sector inherent risks including regulatory approval uncertainties, clinical trial failures, and patent cliff exposure
- Moderate capital efficiency with ROE of 5.8% and ROA of 4.0% suggesting potential capital deployment challenges
- Revenue concentration risk and dependency on successful commercialization of limited product portfolio
Key Metrics to Watch
- Revenue growth rate sustainability and product pipeline progress
- Operating margin maintenance and ability to sustain 23%+ margins at scale
- Free cash flow generation trends and capital allocation strategy for cash deployment
Financial Metrics
Revenue
814.5M
Net Income
197.9M
EPS (Diluted)
$1.91
Free Cash Flow
136.7M
Total Assets
4.9B
Cash
266.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
23.7%
Net Margin
24.3%
ROE
5.8%
ROA
4.0%
FCF Margin
16.8%
Balance Sheet & Liquidity
Current Ratio
2.93x
Quick Ratio
2.85x
Debt/Equity
0.00x
Debt/Assets
30.5%
Interest Coverage
175.82x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T09:55:41.775117 |
Data as of: 2026-03-31 |
Powered by Claude AI